-transparent.png){kind=logo}
The acute effects of ibopamine, a new, orally active dopaminergic agent, were assessed invasively in 8 patients with congestive heart failure (NYHA Class IV). The cardiac Index increased (P less than 0.01) and preload and afterload decreased (P less than 0.05) after a single mean dose of ibopamine 1.4 mg/kg. The peak effect occurred after 1 to 3 h and activity was still demonstrable after 4 to 6 h. There was no change in blood pressure, heart rate or rhythm. No clinical evidence of cardiac toxicity or side effects was noted. Oral ibopamine shows promise in the treatment of congestive heart failure, but more extensive studies after chronic treatment are desirable.
Related Publications
J Col, and
E Mievis, and
M Reynaert
January 1984,
European journal of clinical pharmacology,
J Col, and
E Mievis, and
M Reynaert
May 1985,
British journal of clinical pharmacology,
J Col, and
E Mievis, and
M Reynaert
July 1997,
Lancet (London, England),
J Col, and
E Mievis, and
M Reynaert
July 1997,
Lancet (London, England),
J Col, and
E Mievis, and
M Reynaert
January 1984,
Journal of cardiovascular pharmacology,
J Col, and
E Mievis, and
M Reynaert
January 1990,
Cardiology,
J Col, and
E Mievis, and
M Reynaert
February 1993,
European heart journal,
J Col, and
E Mievis, and
M Reynaert
January 1990,
Journal of autonomic pharmacology,
J Col, and
E Mievis, and
M Reynaert
February 1998,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
J Col, and
E Mievis, and
M Reynaert
February 1986,
Arzneimittel-Forschung,
